In the current study, we present a rat model of NAFLD developed over 8 weeks on a modified FFD with a CCL4 micro dose (0.5 ml CCl4/kg bwt) that captures steatosis, inflammation and fibrosis stages of NAFLD. Here, CCL4 is linked to metabolic dysfunction-associated steatotic liver disease.